2013
Relative effectiveness of letrozole alone or in sequence with tamoxifen for patients diagnosed with invasive lobular carcinoma.
Metzger Filho O, Giobbie-Hurder A, Mallon E, Viale G, Winer E, Thurlimann B, Gelber R, Regan M, Colleoni M, Ejlertsen B, Bonnefoi H, Forbes J, Neven P, Wardley A, Lang I, Smith I, Price K, Coates A, Goldhirsch A. Relative effectiveness of letrozole alone or in sequence with tamoxifen for patients diagnosed with invasive lobular carcinoma. Journal Of Clinical Oncology 2013, 31: 529-529. DOI: 10.1200/jco.2013.31.15_suppl.529.Peer-Reviewed Original ResearchMagnitude of benefitMonotherapy armYears of tamoxifenPost-menopausal womenInvasive lobular carcinomaILC patientsBetter DFSBIG 1Early BCClinicopathological variablesHistological subtypesLobular carcinomaILC subsetsPatientsTreatment assignmentDFSSignificant predictorsTamoxifenHistologyIDCGreater magnitudeClassic ILCOSArmPrevious data
2009
The Yale University Experience of Early‐Stage Invasive Lobular Carcinoma (ILC) and Invasive Ductal Carcinoma (IDC) Treated with Breast Conservation Treatment (BCT): Analysis of Clinical‐Pathologic Features, Long‐Term Outcomes, and Molecular Expression of COX‐2, Bcl‐2, and p53 as a Function of Histology
Moran MS, Yang Q, Haffty BG. The Yale University Experience of Early‐Stage Invasive Lobular Carcinoma (ILC) and Invasive Ductal Carcinoma (IDC) Treated with Breast Conservation Treatment (BCT): Analysis of Clinical‐Pathologic Features, Long‐Term Outcomes, and Molecular Expression of COX‐2, Bcl‐2, and p53 as a Function of Histology. The Breast Journal 2009, 15: 571-578. PMID: 19995377, DOI: 10.1111/j.1524-4741.2009.00833.x.Peer-Reviewed Original ResearchConceptsBreast conservation treatmentInvasive lobular carcinomaInvasive ductal carcinomaEarly-stage invasive lobular carcinomaClinical-pathologic featuresContralateral breast cancerCOX-2Breast relapseILC patientsDuctal carcinomaBreast cancerER/PR/HERBcl-2Cause-specific survivalLong-term outcomesTriple-negative tumorsChemo-preventive strategiesYears of ageImmuno-histochemical analysisExpression of p53Function of histologyDistant relapseInvasive lobularNodal statusContralateral breast
2006
Is histology (His) relevant in adjuvant (Adj)/neoadjuvant (NA) therapy of breast cancer (BC)?
Katz A, Saad E, Pusztai L. Is histology (His) relevant in adjuvant (Adj)/neoadjuvant (NA) therapy of breast cancer (BC)? Journal Of Clinical Oncology 2006, 24: 10541-10541. DOI: 10.1200/jco.2006.24.18_suppl.10541.Peer-Reviewed Original ResearchInvasive lobular carcinomaHormone therapyILC patientsRandomized trialsInvasive ductal carcinomaNA chemotherapyBreast cancerNA therapyPCR rateRetrospective seriesEstrogen receptorPhase III randomized trialsPathologic response rateRole of chemotherapyIndependent predictive factorsOngoing randomized trialsEarly breast cancerFuture randomized trialsInvasive breast cancerDistinct clinical behaviorPotential therapeutic implicationsAdjuvant trialsCT regimensPossible overtreatmentIDC patients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply